Ozempic Click Counting: A Published Chart, Six Canadian Pen Variants and One Important Warning

Educational review — November 4, 2026. “Which Ozempic pen?” is not a minor detail when someone asks about click counting. The Canadian product monograph now describes six pen variants. Some share the same total medicine content but have different labelled dose options. A chart headed only “4 mg pen” can therefore leave out information needed to understand it.

This article examines what one clinic handout reports and explains why it is not interchangeable with manufacturer instructions. The banner is not a prescription or a recommendation to select an unmarked dose. Patients should not change their dose, purchase a different-strength pen or carry a click number across a refill without a clear plan from their prescriber and pharmacist.

The key points

• Read the per-dose label, not just the total milligrams. A total-content number does not uniquely identify every Canadian Ozempic pen.
• Reported counts are not approved settings. Novo Nordisk’s instructions tell users not to count pen clicks.
• Different brands are different devices. Sharing the ingredient semaglutide does not establish a shared mechanical conversion.

What the clinic chart actually reports

The BCDiabetes handout dated August 26, 2026 associates 18, 36, 54 and 72 clicks with targets of 0.25, 0.5, 0.75 and 1 mg for an Ozempic 4 mg pen at 1.34 mg/mL, describing a 1 mg target. Our banner reproduces those numerical claims in an original comparison layout, with the limitation attached. It does not validate their accuracy.

Source: BCDiabetes semaglutide comparison (Aug 26, 2026).Reported counts—not manufacturer-validated settings.

SOURCE REPORT — NOT A VALIDATED DOSING GUIDE. Novo Nordisk says not to count pen clicks.

Those values follow a simple ratio: 18, 36 and 54 are one-quarter, one-half and three-quarters of 72. That internal pattern explains the chart, but a ratio alone cannot tell a reader the volume delivered by each mechanical increment. We have not measured the device or established delivery accuracy at unmarked positions. A dose counter displaying a labelled dose and an audible increment are not equivalent kinds of evidence.

Six variants make shorthand risky

The July 13, 2026 Canadian monograph lists the presentations below. This is a map of labelled products, not a click-conversion table or a statement that every format is currently available at every pharmacy.

The 4 mg rows demonstrate the problem: total contents and volume can match while the dose selector is labelled differently. Colour-based descriptions, an old screenshot or a remembered number are not enough to identify a current presentation. The specific instructions supplied with the pen take precedence over shorthand such as “the blue pen” or “the large pen.”

The manufacturer directs patients to use the dose counter and pointer, not count clicks. It warns that the sounds vary with turning direction. Its Canadian in-use period is eight weeks under the stated storage conditions. Dividing a pen’s nominal contents by a smaller dose does not authorize using it beyond that period.

Why a generic substitution needs a fresh device check

The clinic’s comparison also describes different click increments for other semaglutide brands. We are not publishing those as substitution instructions. The relevant point is narrower: an ingredient name or concentration is not a mechanical specification. A dose expressed in milligrams can be reconciled across a medication record; an unexplained count belongs to a particular device and technique.

That distinction matters during a refill, transfer between pharmacies or change in coverage. If a patient has been following nonstandard directions, changing the product without reconciling those directions can leave two people using the same words to mean different things. This is a reason to check the actual medicine and written plan, not to assume that one online chart supplies a universal answer.

Practice guidance for pharmacists

ISMP’s click-counting safety article highlights discrepancies between verbal instructions, pharmacy labels and medication records, as well as distraction and counting difficulties. These are communication risks, not a demonstration that a particular chart is accurate.

1. Verify brand, Drug Identification Number, total contents, concentration and labelled selectable dose at each relevant change.
2. Ask the patient to describe their actual dose in milligrams, frequency and any nonstandard device instructions.
3. Resolve discrepancies with the prescriber before carrying an old click instruction onto a new presentation.
4. Record the agreed regimen consistently and use teach-back, especially when multiple injectable medicines are involved.
5. Check first-use dates, storage and needle supply rather than estimating usable weeks from the liquid remaining.

What an accurate answer looks like

An accurate answer may be more specific than a single number: it identifies the exact pen, the intended treatment dose, the approved instructions and any separately agreed off-label plan. The chart here documents a published source, while the rest of the article explains its limits. It should prompt that conversation, not replace it.